i thought this was interesting with rats:
Accordingly, GLP-1R agonists are presumed to act as insulin secretagogues in the presence of high glucose levels. To examine this property of myricetin (structure in Fig. 1), pancreatic islets isolated from Wistar rats were incubated in either normal-glucose (3.3 mM) or high-glucose (16.7 mM) medium. Neither GLP-1 nor myricetin stimulated the secretion of insulin into the medium after 90 min of incubation at the normal glucose level (3.3 mM) (Fig. 2A). However, in this condition, the incubation of islets with sulfonylurea glibenclamide (5 μM) led to a significant increase in the insulin concentration in the incubation mixture. As an agonist of GLP-1R in islets, GLP-1 exhibited the appropriate insulinotropic properties in the high-glucose concentration of 16.7 mM. As predicted, the treatment of the islets with myricetin in the high-glucose condition caused a 3-fold increase in the insulin level
The physiologic properties of glucagon-like peptide 1 (GLP-1) make it a potent candidate drug target in the treatment of type 2 diabetes mellitus (T2DM). GLP-1 is capable of regulating the blood glucose level by insulin secretion after administration ...
www.ncbi.nlm.nih.gov